CCR5 and melanoma: In addition, patients with a mutated CCR5 variant were reported to be resistant to prostate cancer development; this is corroborated by the evidence that CCR5+ MDSCs from melanoma patients displayed a more immunosuppressive pattern compared to the CCR5− counterpart [132].